Pharsight

Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(2 years from now)

US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(5 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(3 months from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)

US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2033

(9 years from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(12 years from now)

Cabometyx is owned by Exelixis Inc.

Cabometyx contains Cabozantinib S-Malate.

Cabometyx has a total of 11 drug patents out of which 0 drug patents have expired.

Cabometyx was authorised for market use on 25 April, 2016.

Cabometyx is available in tablet;oral dosage forms.

Cabometyx can be used as treatment of advanced renal cell carcinoma, treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy, treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy, treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib.

Drug patent challenges can be filed against Cabometyx from 29 November, 2016.

The generics of Cabometyx are possible to be released after 17 April, 2037.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
New Indication(I-854) Jan 22, 2024
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028
New Indication(I-873) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Indication(I-760) Dec 19, 2020
New Product(NP) Apr 25, 2019
New Indication(I-792) Jan 14, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma; Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy; Treatment of patients with hepatocellular carcinoma (...

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents